vs
Side-by-side financial comparison of Korro Bio, Inc. (KRRO) and Lakeshore Acquisition III Corp. (LCCC). Click either name above to swap in a different company.
Korro Bio, Inc. is the larger business by last-quarter revenue ($1.3M vs $717.3K, roughly 1.8× Lakeshore Acquisition III Corp.).
Korro Bio, Inc. is a clinical-stage biotechnology company focused on developing innovative RNA editing therapies for rare and severe genetic diseases. It leverages its proprietary oligonucleotide platform to target disease-causing mutations, with core pipelines covering ophthalmology, respiratory and neuromuscular disorder segments, striving to address unmet medical needs for global patients.
KRRO vs LCCC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $717.3K |
| Net Profit | — | $486.8K |
| Gross Margin | — | — |
| Operating Margin | — | -32.1% |
| Net Margin | — | 67.9% |
| Revenue YoY | -43.1% | — |
| Net Profit YoY | -136.1% | — |
| EPS (diluted) | — | $0.08 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.1M | $717.3K | ||
| Q2 25 | $1.5M | $467.3K | ||
| Q1 25 | $2.5M | — | ||
| Q3 24 | $0 | — | ||
| Q2 24 | $0 | — | ||
| Q1 24 | $0 | — |
| Q4 25 | — | — | ||
| Q3 25 | $-18.1M | $486.8K | ||
| Q2 25 | $-25.8M | $216.5K | ||
| Q1 25 | $-23.4M | — | ||
| Q3 24 | $-21.0M | — | ||
| Q2 24 | $-21.8M | — | ||
| Q1 24 | $-19.6M | — |
| Q4 25 | — | — | ||
| Q3 25 | -1764.9% | -32.1% | ||
| Q2 25 | -1863.2% | -53.7% | ||
| Q1 25 | -981.2% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | -1657.0% | 67.9% | ||
| Q2 25 | -1765.1% | 46.3% | ||
| Q1 25 | -917.1% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-1.92 | $0.08 | ||
| Q2 25 | $-2.74 | $0.06 | ||
| Q1 25 | $-2.49 | — | ||
| Q3 24 | $-2.26 | — | ||
| Q2 24 | $-2.43 | — | ||
| Q1 24 | $-2.44 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $75.2M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $51.4M | $-1.6M |
| Total Assets | $113.5M | $71.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.2M | — | ||
| Q3 25 | $92.5M | — | ||
| Q2 25 | $96.4M | — | ||
| Q1 25 | $115.0M | — | ||
| Q3 24 | $137.0M | — | ||
| Q2 24 | $157.4M | — | ||
| Q1 24 | $138.8M | — |
| Q4 25 | $51.4M | — | ||
| Q3 25 | $99.0M | $-1.6M | ||
| Q2 25 | $115.1M | $-1.4M | ||
| Q1 25 | $139.0M | — | ||
| Q3 24 | $179.6M | — | ||
| Q2 24 | $198.1M | — | ||
| Q1 24 | $151.4M | — |
| Q4 25 | $113.5M | — | ||
| Q3 25 | $161.6M | $71.0M | ||
| Q2 25 | $180.4M | $70.5M | ||
| Q1 25 | $202.2M | — | ||
| Q3 24 | $243.5M | — | ||
| Q2 24 | $249.6M | — | ||
| Q1 24 | $198.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-78.6M | $-206.3K |
| Free Cash FlowOCF − Capex | $-79.1M | — |
| FCF MarginFCF / Revenue | -6120.7% | — |
| Capex IntensityCapex / Revenue | 40.1% | — |
| Cash ConversionOCF / Net Profit | — | -0.42× |
| TTM Free Cash FlowTrailing 4 quarters | $-140.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-78.6M | — | ||
| Q3 25 | $-17.2M | $-206.3K | ||
| Q2 25 | $-19.2M | $-218.3K | ||
| Q1 25 | $-24.5M | — | ||
| Q3 24 | $-16.1M | — | ||
| Q2 24 | $-14.6M | — | ||
| Q1 24 | $-21.9M | — |
| Q4 25 | $-79.1M | — | ||
| Q3 25 | $-17.4M | — | ||
| Q2 25 | $-19.4M | — | ||
| Q1 25 | $-24.6M | — | ||
| Q3 24 | $-21.0M | — | ||
| Q2 24 | $-20.6M | — | ||
| Q1 24 | $-27.5M | — |
| Q4 25 | -6120.7% | — | ||
| Q3 25 | -1592.1% | — | ||
| Q2 25 | -1326.6% | — | ||
| Q1 25 | -963.6% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 40.1% | — | ||
| Q3 25 | 16.1% | — | ||
| Q2 25 | 9.6% | — | ||
| Q1 25 | 4.7% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -0.42× | ||
| Q2 25 | — | -1.01× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
